Hemispherx Hopes To Ride Retrovirus Discovery To Ampligen Approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
One year after receiving an extensive “complete response” letter for the chronic fatigue syndrome therapy Ampligen (rintatolimod), Hemispherx Biopharma, Inc. is working to revivify the drug’s clinical prospects by applying recent discoveries about the potential role of a retrovirus in CFS to its dataset.